Clinical trial NCT04808011: A Single Arm, Multi-Center Study To Evaluate The Intelligent Dialysis Assistant (IDA)
Official title: A Single Arm, Prospective, Open Label, Cross-Over, Multi-Center Study to Evaluate the Safety, Feasability and Usability of the Intelligent Dialysis Assistant (IDA)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Kidney Disease Stage 5
Lead sponsor: liberDi Ltd.
Sponsor class: INDUSTRY
First posted: 2021-03-19
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: The subjects will undergo a single peritoneal dialysis exchange procedure at the PD clinic, under the supervision of the medical staff and instructed about its operation. Further exchanges will be performed by the subjects themselves at home.

The study includes two cohorts and two phases: in the first phase (phase I), 20 subjects will be recruited as Cohort 1 to undergo a single exchange in the medical center using the IDA. Following the completion of recruitment of all 20 subjects and the performance of the single on site exchange, the Sponsor will perform an interim analysis of the results for safety and initial feasibility, followed by submission of the results to the MoH and approval of the second phase (phase II).

Subjects will be treated with their routine dialysis device for 14 days, followed by a treatment with the IDA for a period of 30 days, and then an additional period of 14 days of treatment with their routine dialysis device.
Primary purpose: TREATMENT

Brief summary: This is a multi-center, open label, cross-over clinical study. A total of 18 subjects will be enrolled to use the IDA for every peritoneal dialysis exchange for 14 days. To participate in the study, the subjects must have current CKD5 and have been treated with PD for at least 3 months. The subjects will undergo a single peritoneal dialysis exchange procedure at the PD clinic, under supervision of the medical staff and instructed about its operation. Further exchanges will be performed by the subjects themselves at home.

The study includes three periods:

1. First period (Observational): 14-day Observational Period. Eligible subjects who sign informed consent will continue with their regular CAPD treatment while performing measurement and recording of dialysate in/out time.
2. Second period (Interventional): 14-day interventional period, where subjects will perform dialysis exchanges using the IDA according to the below visit schedule.
3. Third period (Follow up): 14-day follow up period, during which the study staff will call the subject once weekly to inquire about device-related SAEs and any changes to concomitant medications.

Detailed description: This is a multi-center, open label, cross-over clinical study. A total of 20 subjects will be enrolled to use the IDA for every peritoneal dialysis exchange for 14 days. To participate in the study, the subjects must have current CKD5 and have been treated with PD for at least 3 months. The subjects will undergo a single peritoneal dialysis exchange procedure at the PD clinic, under supervision of the medical staff and instructed about its operation. Further exchanges will be performed by the subjects themselves at home.

The study includes two cohorts and two phases: in the first phase (phase I), 20 subjects will be recruited as Cohort 1 to undergo a single exchange in the medical center using the IDA. Following the completion of recruitment of all 20 subjects and the performance of the single on site exchange, the Sponsor will perform an interim analysis of the results for safety and initial feasibility, followed by submission of the results to the MoH and approval of the second phase (phase II). The expected timeframe between phase I and phase II is up to 4 weeks. An additional cohort, Cohort 2, will be added to Phase I, which will include additional ten (10) subjects. These subjects will undergo the same procedure at the dialysis clinic, with the addition of blood sampling for CBC and Chemistry two (2) hours ±30 minutes after the procedure. A total of 20 subjects from either cohort, meeting the inclusion and exclusion criteria of Cohort 1, will continue to complete the second phase of the study (Phase II).

Phase II of the study includes three periods:

First period (Observational): 14-day Observational Period. Eligible subjects who sign informed consent will continue with their regular CAPD treatment while performing measurement and recording of dialysate in/out time.

Second period (Interventional): 14-day interventional period, where subjects will perform dialysis exchanges using the IDA according to the below visit schedule.

Third period (Follow up): 14-day follow up period, during which the study staff will call the subject once weekly to inquire about device-related SAEs and any changes to concomitant medications.

Eligibility criteria: Inclusion Criteria:

* Subjects with CKD stage 5 treated by continuous ambulatory peritoneal dialysis (CAPD)
* Male or female, Age \>18 years
* Mental ability to understand study procedures and provide an informed consent
* More than 3 months on PD (Peritoneal Dialysis)
* At least 3 daily exchanges
* Self-treated subject
* Stable PD prescription for the last month

Exclusion Criteria:

* Need of cycler (APD, Automated Peritoneal Dialysis)
* Known mechanical problem (drainage, fill) during the last month prior to enrollment
* Pregnant or breastfeeding women
* subject who is unwilling or unable to comply with study procedures
* Known Peritonitis or other catheter associated infections during the last 3 months prior to enrollment
* Known Congestive heart failure stage III- IV
* Non-elective hospitalization during the last 3 months prior to enrollment
* Any other medical or mental condition, that at the investigator's discretion may prevent the subject from participating in the study
* Participation in any other clinical study within 4 weeks prior to enrollment

Primary outcomes:
measure: Device-Related Serious Adverse Event Incidence
timeFrame: 14 days
measure: AE during on site exchange
timeFrame: 1 day
Secondary outcomes:
measure: Procedure Time Length
timeFrame: 14 days
measure: Usability Questionnaire
timeFrame: 14 days
measure: Device-Related Serious Adverse Events Incidence During Follow Up Period
timeFrame: 14 days
measure: Renal Treatment Internal Questionnaire
timeFrame: 42 days
Other outcomes:
Locations:
city: Be'er Sheva
country: Israel
facility: Soroka Medical Center
city: Haifa
country: Israel
facility: Carmel MC
city: Kfar Saba
country: Israel
facility: Meir Medical Center
Study officials:
affiliation: Carmel MC, Haifa
name: Tatiana Tansyochuk, MD
role: PRINCIPAL_INVESTIGATOR
References: